Global NGS Informatics and Clinical Genomics Market 2018-2028: The Wave of Data Types - NGS Data Remains the Leading Data Type for Precision Medicine
DUBLIN, Nov. 12, 2018 /PRNewswire/ --
The "Global NGS Informatics and Clinical Genomics Market: Focus on Product Types (LIMS, Data Analysis and Interpretation Tools, and Storage and Computing Solutions), End Users, and Regional Analysis for 21 Countries: Analysis and Forecast (2018-2028)" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
With 54% share in all the business strategies adopted by companies, partnership and collaborations seem to be the strategy of choice for companies to enter into this market. Companies are focusing on novel software product development and launch to secure early mover's advantage in the market with this strategy accounting for 18% of the total strategies employed.
Furthermore, the NGS informatics and clinical genomics market is witnessing a steep rise in the launch of new informatics tools. The average frequency of product launched in this market is 10-12 a year. The products available in the global NGS informatics and clinical genomics market encompasses a wide range of software products, platforms and services used for computing, and analysing, interpretation, and storing of NGS data. The market also consists of on-premise as well as cloud-based solutions offering a wide range of primary, secondary, and tertiary (analysis and reporting) of NGS generated data.
As of 2018, NGS informatics services is the largest product segment in this market. These services are often provided by NGS instrument providers such as Illumina and ThermoFisher Scientific, among others. With the maturity of the market, the demand for these services will surge due to shift in the end user preference for seamless end-to-end genomic solutions at competitive prices.
The NGS informatics and clinical genomics market has five major end users namely: academic research institutes, biopharmaceutical companies, diagnostic companies, government agencies, and hospitals and clinics. These end users group adopt NGS informatics solutions for a wide range of purposes. As of 2017, the academics and research institutes served as the leading end user segment of the market holding a share of approximately 41% of the overall market.
However, biopharmaceutical companies followed by hospitals and clinics are expected to be the leading end-user segments in this market growing with a CAGR of 22.02% and 21.66% respectively, during the forecast period. The reason for this high growth is primarily due to multiple factors such as rising popularity of NGS-based tests among the healthcare organizations, increasing use of NGS tests in drug discovery, and clinical trial, among others.
The global NGS informatics and clinical genomics market encompasses major regions such as North America, Europe, Asia-Pacific, Middle East and Africa, and Rest-of-the-World (RoW). North America is the leading region in the NGS informatics and clinical genomics market accounting for approximately 45.45% and has an estimated value of $380.0 million (as of 2017). The U.S. is the clear regional leader in the North America market with an estimated value of $361.0 million. The major reason for the growth in this region is the rapidly increasing number of genomics projects funded by government which will be providing millions of dollars for the next couple of years to have thousands of patient genomes sequenced.
The dynamics of the overall market depicts that the NGS informatics and clinical genomics space offers huge profitability to investors willing to enter the market. The year 2017 witnessed numerous series of fundings from investors to companies working on data management, analysis, and interpretation of NGS data. For example, companies such as Genoox have been potentially funded ($6 million investment) by Inimiti Capital and Glilot Capital Partners (two Israeli venture capital firms) for developing a platform for interpretation of NGS data through a search engine. A plethora of companies are being invested in for their innovations toward data interpretation and visualization. In the years to come, the scope and scale of sequencing projects will further evolve as the throughput per sample will significantly surge and the cost of sequencing further plummets.
Key Topics Covered:
Executive Summary
1 Market Overview
1.1 Introduction to NGS Informatics and Clinical Genomics
1.2 Cost of NGS Data Analysis
1.3 Role of NGS Informatics in Precision Medicine?
1.4 Approach to Precision Medicine
1.5 Evolution of Precision Medicine Technology
1.6 The Wave of Data Types: NGS Data Remains the Leading Data Type for Precision Medicine
1.6.1 Overview
1.6.2 Genomic Data
1.6.3 Lifestyle and Environment
1.6.4 Health Information
1.6.5 Social Media
1.7 Healthcare Information Technology: A Boon for NGS informatics Market
1.8 The Correlation Between NGS Informatics and Clinical Genomics
1.9 Technologies with the Potential to Incorporate NGS in a Clinical Setting
1.9.1 Electronic Health Records (EHR)
1.9.2 Health Information Exchange
1.9.3 Clinical Decision Support Systems (CDSS)
1.9.4 Population Health Management (PHM)
1.9.5 Blockchain
1.9.6 Artifical Intelligence/Machine Learning
1.9.7 Big Data Analytics
2 Market Dynamics
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Low cost Sequencing Platforms
2.2.2 Growth in Clinical Application
2.2.3 Rise in Genomic Data
2.2.4 Increasing Number of Population Genomics Initiatives
2.2.5 Advancements in Big Data Technology
2.2.6 Reducing Cost of Cloud Storage
2.3 Market Restraints
2.3.1 Lack of Integration and Interoperability among Existing Information Systems
2.3.2 Patient Access to Data
2.3.3 Data Security and Privacy
2.3.4 Fragmented Research Environment
2.4 Market Opportunities
2.4.1 Cross Industry Collaborations between Health Systems, Academia and Health IT Industry
2.4.2 Investment in Blockchain Technology and Information Security
2.4.3 Clinical Application Focussed NGS Informatics Products
2.4.4 Integration of Clinical and Non-Clinical NGS data
2.4.5 Automation of Sequencing and Interpretation
3 Competitive Insights
3.1 Key Strategies and Developments
3.1.1 Partnerships, Joint Ventures, and Collaborations
3.1.2 Product Development and Launch
3.1.3 Business Funding and Contracts
3.1.4 Mergers and Acquisitions
3.1.5 Approvals and Certifications
3.1.6 Others
3.2 Competitive Scenario: Intense Competition within a Converging Market
4 Industry Attractiveness and Insights
4.1 Porter's Five Forces Analysis
4.2 Bargaining Power of Suppliers
4.3 Bargaining Power of Buyer
4.4 Threat of New Entrants
4.4.1 Threat of Substitute Products
4.4.2 Intensity of Competitive Rivalry
5 Key Industry Insights
5.1 Introduction
5.2 Regulatory Bodies
6 Global NGS Informatics and Clinical Genomics Market: Analysis and Forecast
6.1 Assumptions & Limitations for Market Size Calculations
7 Global NGS Informatics and Clinical Genomics Market (by Technology)
7.1 Overview
7.1.1 Blockchain Genomics Platforms
7.1.2 Data Aggregation Software
7.1.3 AI/Machine Learning and Cloud Computing based Genomic Platforms
7.1.4 Clinical Decision Support based Genomic Platforms
7.1.5 Artificial Intelligence (AI) based Drug Discovery Platforms
8 Global NGS Informatics and Clinical Genomics Market (by Product Type)
8.1 Laboratory Information Management Systems (LIMS)
8.2 NGS Informatics Services (Includes both Sequencing and Consulting Services)
8.3 Commercial Primary and Secondary Data Analysis Tools
8.3.1 Primary Data Analysis
8.3.2 Secondary Data Analysis
8.4 Storage, Infrastructure, and Computing
8.5 Interpretation (Tertiary Analysis) Tools
9 Global NGS Informatics and Clinical Genomics Market (by End User)
9.1 Academics and Research Institutes
9.2 Biopharmaceutical Industry
9.3 Diagnostic Industry
9.4 Government Agencies
9.5 Hospitals and Clinics
10 Global NGS Informatics and Clinical Genomics Market (by Region)
11 Company Profiles
-- 2bPrecise, LLC
-- Amazon Web Services, Inc.
-- Beijing Genomic Institute (BGI)
-- Cota, Inc.
-- CureMatch, Inc.
-- DNASTAR
-- DNAnexus, Inc.
-- DrChrono Inc.
-- Eagle Genomics
-- Edico Genome
-- Epic Systems Corporation
-- F. Hoffmann-La Roche AG
-- Fabric Genomics, Inc. (Formerly Omicia, Inc.)
-- Flatiron Health, Inc. (Subsidiary of Roche Group Company)
-- Genalice
-- GenomOncology, LLC
-- Genomatix AG
-- IBM Corporation
-- Illumina, Inc.
-- Interpreta, Inc.
-- Koninklijke Philips N.V.
-- LunaDNA Inc.
-- N-of-One, Inc.
-- NantHealth, Inc.
-- Navican Genomics, Inc.
-- Orion Health Group Limited
-- Partek Incorporated
-- QIAGEN N.V.
-- SAP SE
-- SOPHiA GENETICS SA
-- Seven Bridges Genomics Inc.
-- Syapse, Inc.
-- Tempus Labs, Inc.
-- Verily Life Sciences LLC
-- WuxiNextCode
For more information about this report visit https://www.researchandmarkets.com/research/82cncx/global_ngs?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
